Panacea Biotec Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Panacea Biotec Ltd with three other
pharmaceutical manufacturers in Asia:
of South Korea
sales of 133.26 billion Korean Won [US$119.26 million]
of which 100%
Chongqing Zhifei Biological Products Co Ltd
(445.92 million Chinese Renmimbi [US$64.79 million]
of which 99%
was Biological Product), and
Essex Bio-Technology Limited
based in Hong Kong
(775.66 million Hong Kong Dollars [US$99.88 million]
Panacea Biotec Ltd reported sales of 6.53 billion Indian Rupees (US$99.79 million)
March of 2016.
decrease of 5.0%
versus 2015, when the company's sales were 6.87 billion Indian Rupees.
Contributing to the drop in overall sales was the 45.1% decline
in Research and Development, from 238.20 million Indian Rupees to 130.80 million Indian Rupees.
There were also decreases in sales in
Formulation (down 0.1% to 3.87 billion Indian Rupees)
Vaccine (down 8.4% to 2.53 billion Indian Rupees)